Results now emerge from a preclinical trial of a heat-shock protein inhibitor in a mouse model of neurodegenerative disease. The data indicate that targeting a misfolded protein for degradation may be a useful therapeutic strategy (pages 1088–1095).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Taylor, J.P., Hardy, J. & Fischbeck, K.H. Science 296, 1991–1995 (2002).
Waza, M.I. et al. Nat Med 11, 1088–1095 (2005).
Sherman, M.Y. & Goldberg, A.L. Neuron 29, 15–32 (2001).
La Spada, A.R. & Taylor, J.P. Neuron 38, 681–684 (2003).
Venkatraman, P. et al. Mol. Cell 14, 95–104 (2004).
Holmberg, C.I., et al. EMBO J. 23, 4307–4318 (2004).
La Spada, A.R., et al. Nature 352, 77–79 (1991).
Vanaja, D.K., et al. Cell Stress Chaperones 7, 55–64 (2002).
Schneider, C. et al. Proc. Natl. Acad. Sci. USA 93, 14536–14541 (1996).
Zu, T. et al. J. Neurosci. 24, 8853–8861 (2004).
Yamamoto, A., Lucas, J.J. & Hen, R. Cell 101, 57–66 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Spada, A., Weydt, P. Targeting toxic proteins for turnover. Nat Med 11, 1052–1053 (2005). https://doi.org/10.1038/nm1005-1052
Issue Date:
DOI: https://doi.org/10.1038/nm1005-1052
This article is cited by
-
Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein
Journal of Molecular Medicine (2006)